Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Medical Oncology
Erschienen in: Medical Oncology 11/2020

01.11.2020 | Review Article

Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma

verfasst von: Danielle Benedict Sacdalan, Marvin Jonne Mendoza, John Paulo Vergara, Lance Isidore Catedral, Frederic Ivan Ting, Louis Mervyn Leones, Carlo Miguel Berba, Dennis L. Sacdalan

Erschienen in: Medical Oncology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Small bowel cancers are rare tumors with an incidence 50–100-fold less than colorectal cancer. These tumors carry a poor prognosis. Owing to its rarity, treatment of this disease, particularly in its advanced stages, has not been optimized and is derived mainly from treatment regimens for colorectal cancer. Based on recent studies bevacizumab, an antibody directed against vascular endothelial growth factor and used in the management of metastatic CRC, has been added to treatment guidelines for metastatic small bowel adenocarcinoma. We investigate in this review the evidence behind other targeted treatments that may be beneficial in the treatment of metastatic small bowel adenocarcinoma. These are agents against EGFR, VEGFR-2, HER2, and NTRK as well as immune checkpoint inhibitors. The last class of drugs appears to hold the greatest promise based on the preponderance of evidence supporting its use. However, overall data remains sparse. Results of studies currently underway will be valuable in shedding more light on the management of this aggressive cancer.
Literatur
1.
Aparicio T, Zaanan A, Mary F, Afchain P, Manfredi S, Evans TR. Small bowel adenocarcinoma. Gastroenterol Clin. 2016;45(3):447–57.
2.
3.
Li J, Wang Z, Liu N, Hao J, Xu X. Small bowel adenocarcinoma of the jejunum: a case report and literature review. World J Surg Oncol. 2016;14(1):177.PubMedPubMedCentral
4.
Dahmus JD, Kotler DL, Kastenberg DM, Kistler CA. The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. J Gastrointest Oncol. 2018;9(4):769.PubMedPubMedCentral
5.
Meng C, Bai C, Brown TD, Hood LE, Tian Q. Human gut microbiota and gastrointestinal cancer. Genom Proteom Bioinform. 2018;16(1):33–49.
6.
Aydin D, Sendur MA, Kefeli U, et al. Evaluation of bevacizumab in advanced small bowel adenocarcinoma. Clin Colorectal Cancer. 2017;16(1):78–83.PubMed
7.
Takayoshi K, Jusaba H, Uenomachi M, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80(2):333–42.PubMed
8.
Kulesza J, Meszka M, Rykala C, et al. Adenocarcinoma of the small bowel—a case report. Pol Prz Chir. 2014;86(6):285–8.
9.
10.
Raghav K, Overman MJ. Small bowel adenocarcinomas—existing evidence and evolving paradigms. Nat Rev Clin Oncol. 2013;10(9):534–44.PubMedPubMedCentral
11.
Vergara JP, Sacdalan DB, Amurao-Amante M, Sacdalan DL. Bevacizumab in metastatic small-bowel adenocarcinoma: a systematic review and meta-analysis. Rare Tumors. 2019;11:2036361318825413.PubMedPubMedCentral
12.
Aparicio T, Svrcek M, Zaanan A, et al. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer. 2013;109(12):3057–66.PubMedPubMedCentral
13.
Rompteaux P, Gagnière J, Gornet JM, Coriat R, Baumgaertner I, Lecomte T, Afchain P, Zaanan A, Pocard M, Bachet JB, Bonichon-Lamichhane N. Resection of small bowel adenocarcinoma metastases: results of the ARCAD-NADEGE cohort study. Eur J Surg Oncol. 2019;45(3):331–5.PubMed
14.
Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene. 2007;26(57):7825–32.PubMed
15.
Hänninen UA, Katainen R, Tanskanen T, Plaketti RM, Laine R, Hamberg J, Ristimäki A, Pukkala E, Taipale M, Mecklin JP, Forsström LM. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLoS Genet. 2018;14(3):e1007200.PubMedPubMedCentral
16.
Schrock AB, Devoe CE, McWilliams R, Sun J, Aparicio T, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol. 2017;3(11):1546–53.PubMedPubMedCentral
17.
18.
19.
Santini D, Fratto ME, Spoto C, Russo A, Galluzzo S, Zoccoli A, Vincenzi B, Tonini G. Cetuximab in small bowel adenocarcinoma: a new friend? Br J Cancer. 2010;103(8):1305–1305.PubMedPubMedCentral
20.
De Dosso S, Molinari F, Martin V, Frattini M, Saletti P. Molecular characterisation and cetuximab-based treatment in a patient with refractory small bowel adenocarcinoma. Gut. 2010;59:1587–9.PubMed
21.
Patel DK. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacother: J Hum Pharmacol Drug Ther. 2008;28(11P2):31S-41S.
22.
23.
Chan OTM, Chen ZE, Chung F, Kawachi K, Phan DC, Himmelfarb E, et al. Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. Amm J Clin Pathol. 2010;134:880–5.
24.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205.PubMedPubMedCentral
25.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9.PubMedPubMedCentral
26.
Normanno N, De LA, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16.PubMed
27.
Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–72.PubMed
28.
29.
30.
Hamad A, Singhi AD, Bahary N, Mcgrath K. Neoadjuvant treatment with trastuzumab and FOLFOX induces a complete pathologic response in a metastatic ERBB2 (HER2)-amplified duodenal cancer. J Natl Compr Canc Netw. 2017;15(8):983–8.PubMed
31.
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.PubMed
32.
Pedersen K, Foster N, Overman M, Boland P, Kim S, Arrambide K, et al. ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA). Ann Oncol. 2019;30:mdz154–6.
33.
34.
Wang Y, Jiang C, Guan J. Molecular alterations of EGFR in small intestinal adenocarcinoma. Int J Color Dis. 2013;28(10):1329–35.
35.
Alvi MA, Mcart DG, Kelly P, Fuchs M, Mccabe CM, Bingham V, et al. Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget. 2015;6(25):20863–74.PubMedPubMedCentral
36.
Rashid A, Hamilton SR. Genetic alterations in sporadic and crohn’s-associated adenocarcinomas of the small intestine. Gastroenterology. 1997;113:127–35.PubMed
37.
Zaaimi Y, Aparicio T, Laurent-Puig P, Taieba J, Zaanan A. Advanced small bowel adenocarcinoma: molecular characteristics and therapeutic perspectives. Clin Res Hepatol Gastroenterol. 2015;40(2):154–60.PubMed
38.
Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, et al. Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of vater. Oncologist. 2018;23:277-e26.PubMed
39.
Yamaguchi Y, Nishidoi H, Shibata S, Ozaki Y, Ueta T, Yamashiro Y, et al. A case report of recurrent small bowel adenocarcinoma successfully treated with monoclonal antibody against EGFR and S-1. Gan To Kagaku Ryoho. 2013;40(13):2577–9.PubMed
40.
41.
Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006;29(1):1–9.PubMed
42.
Singh Kanwar S, Nautiyal J, Majumdar PN. EGFR (S) inhibitors in the treatment of gastro-intestinal cancers: what’s new? Curr Drug Targets. 2010;11(6):682–98.
43.
Akiyama N, Karayama M, Iwaizumi M, Kusama Y, Kono M, Hozumi H, et al. Synchronous duodenal cancer and lung cancer harboring an epidermal growth factor receptor mutation treated with erlotinib and oral fluoropyrimidine. Intern Med. 2017;56:2367–71.PubMedPubMedCentral
44.
Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs. 2017;35(1):95–104.PubMed
45.
46.
Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–87.PubMedPubMedCentral
47.
Olayioye MA. Intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001;3(6):385.PubMedPubMedCentral
48.
Citri A, Yarden Y. EGF–ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505–16.PubMed
49.
Quaas A, Heydt C, Waldschmidt D, Alakus H, Zander T, Goeser T, et al. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma. BMC Gastroenterol. 2019;19(21):1–6.
50.
Farzand S, Siddique T, Saba K, Bukhari MH. Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system. World J Gastroenterol. 2014;20(19):5889–96.PubMedPubMedCentral
51.
Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010;102(1):144–50.PubMed
52.
Cutsem EV, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol. 2009;27(Suppl):18s. https://​doi.​org/​10.​1200/​jco.​2009.​27.​18_​suppl.​lba4509.CrossRef
53.
54.
Braga VM, De Oliveira MB, Netto CC, El Ibrahim R, Peixoto RD. Human epidermal growth factor receptor 2-positive duodenal adenocarcinoma: a case report and review of the literature. Case Rep Oncol. 2015;001(8):285–9.
55.
Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol. 2018;2:1–20.
56.
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–47.PubMedPubMedCentral
57.
Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023.PubMedPubMedCentral
58.
59.
Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531–54.PubMedPubMedCentral
60.
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82.PubMed
61.
62.
63.
64.
Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. OncoTargets Ther. 2018;11:955.
65.
Webb ES, Liu P, Baleeiro R, et al. Immune checkpoint inhibitors in cancer therapy. J Biomed Res. 2018;32(5):317–26.PubMed
66.
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.PubMed
67.
Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384–91.PubMedPubMedCentral
68.
Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7–H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499–505.PubMed
69.
Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. BMC Cancer. 2019;19:273.PubMedPubMedCentral
70.
Wu C, Zhu Y, Jiang J, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006;108(1):19–24.PubMed
71.
72.
Daud AI, Wolchok JD, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34(34):4102–9.PubMedPubMedCentral
73.
Skov B, Rørvig S, Jensen T, et al. The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. Mod Pathol. 2020;33:109–17.PubMed
74.
Kammerer-Jacquet SF, Deleuze A, Saout J, et al. Targeting the PD-1/PD-L1 pathway in renal cell carcinoma. Int J Mol Sci. 2019;20(7):1692.PubMedCentral
75.
76.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–33.PubMed
77.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92.PubMed
78.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.PubMedPubMedCentral
79.
Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
80.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
81.
Williams AS, Huang WY. The analysis of microsatellite instability in extracolonic gastrointestinal malignancy. Pathology. 2013;45:540–52.PubMed
82.
Meltzer SJ, Yin J, Manin B, et al. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett’s-associated esophageal adenocarcinomas. Cancer Res. 1994;54(3379–82):75.
83.
Nakata B, Wang YQ, Yashiro M, et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res. 2002;8(2536–40):76.
84.
Agaram NP, Shia J, Tang LH, Klimstra DS. DNA mismatch repair deficiency in ampullary carcinoma: a morphologic and immunohistochemical study of 54 cases. Am J Clin Pathol. 2010;133(772–80):77.
85.
Watari J, Mitani S, Ito C, et al. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: associations among clinicopathological, immunophenotypic and molecular features. Sci Rep. 2019;9:10526.PubMedPubMedCentral
86.
Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154:1805–13.PubMedPubMedCentral
87.
Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417–22.PubMed
88.
Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527–35.PubMedPubMedCentral
89.
Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51.PubMed
90.
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.PubMedPubMedCentral
91.
92.
93.
Metadaten
Titel
Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma
verfasst von
Danielle Benedict Sacdalan
Marvin Jonne Mendoza
John Paulo Vergara
Lance Isidore Catedral
Frederic Ivan Ting
Louis Mervyn Leones
Carlo Miguel Berba
Dennis L. Sacdalan
Publikationsdatum
01.11.2020
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 11/2020
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-020-01432-3

Weitere Artikel der Ausgabe 11/2020

Medical Oncology 11/2020 Zur Ausgabe

Original Paper

The investigation of the healing effect of active ingredients in traditional medicinal plants on lung cancer

Review Article

Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia

Original Paper

The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era

Original Paper

Organoid culture system for patient-derived lung metastatic osteosarcoma

Original Paper

The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway

Original Paper

The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise